Global Systemic Inflammatory Response Syndrome Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Systemic Inflammatory Response Syndrome Treatment Market size was valued at USD 8.5 billion in 2024 and is projected to reach USD 18.8 billion by the end of 2037, rising at a CAGR of 7% during the forecast period, i.e., 2025-2037. In 2025, the industry size of systemic inflammatory response syndrome treatment is estimated at USD 9.2 billion.
One of the major drivers behind the exponential growth in the market is the increasing incidence of sepsis across the globe. As per WHO, the annual prevalence of this ailment was 49.4 million in 2020, with a mortality rate of 20.3%. This is magnifying the surge for urgent and effective clinical and pharmaceutical solutions in dedicated medical settings. In 2022, an AHRQ study revealed that the early-stage use of therapeutics for systemic inflammatory response syndrome (SIRS) reduced the need for hospitalization in the U.S. by 22.1%. It also mentioned that this approach of preventive intervention pushed healthcare savings in the country up to USD 2.0 billion.
Various factors, such as the heightened cost of active pharmaceutical ingredients (APIs) and additional expenses on the elongated regulatory approval process, are fostering economic disparity in the market. For instance, between 2022 and 2023, the producer price index (PPI) of medicines for SIRS in the U.S. rose by a 4.5% year-over-year (YoY) increment. Similarly, the consumer price index (CPI) was augmented with a 6.4% YoY for treatments administered in hospitals. Furthermore, associated companies and academia are rigorously conducting R&D to explore and establish more cost-effective production and distribution methods. This can further be testified by the emphasized global trade value of SIRS-related pharmaceutical raw materials, which surpassed USD 19.0 billion in 2022.
Systemic Inflammatory Response Syndrome Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Investments and efforts in innovation: The clinically proven enhancement in product efficacy due to extended R&D conducted is inspiring companies to invest more in explorations. Testifying to this fact, the world recorded an annual business value of USD 3.4 billion in 2023 for raw materials used in clinical studies on sepsis and inflammatory response to therapeutics. Furthermore, the integration of advanced technologies in both development and manufacturing is leveraging the capacities of the systemic inflammatory response syndrome treatment market in both therapeutic excellence and product accessibility. For instance, in 2023, automated production lines of SIRS treatment-related tools reduced delays by 15.3% in North America, Germany, and Japan.
- The steady capital influx across leading landscapes: With continuous efforts from public and private investors to improve public access to proper care, the cash inflow in the market is magnifying. For instance, in 2023, the U.S. Medicare expenditure on related curatives, such as vasopressors and biologics, increased by 9.3% YoY from the previous year, reaching USD 4.5 billion. Simultaneously, the increment in per capita and disposable income of developed and emerging economies is also securing a profitable revenue generation in this sector. In this regard, KFF reported that the average out-of-pocket spending on therapeutics for each SIRS patient was USD 1209.1 per year in 2023.
Historical Patient Growth Analysis: Shaping the Future of SIRS Treatment Demand
Both developed and emerging countries around the world witnessed a significant rise in worsened cases of SIRS, requiring hospitalization and ICU admission. This enlarging demography is highly attributable to the lack of early diagnosis and the rapidly aging population. Additionally, the influence of rising incidences of hospital-acquired infections (HAI), post-surgical complications, and inflammatory chronic disease symptoms is fuelling the volume of the patient pool in the systemic inflammatory response syndrome treatment market. Moreover, this expansion in consumer base is creating new opportunities for global leaders in this field through healthcare reformations and infrastructural resource affiliations.
Statistical Historical Patient Growth Data (2010-2020)
|
Country |
2010 SIRS Patient Count (in million) |
2020 SIRS Patient Count (in million) |
Growth Rate (in %) |
|
U.S. |
1.5 |
2.0 |
42.3% |
|
Germany |
0.7 |
0.8 |
28.1% |
|
France |
0.6 |
0.7 |
23.4% |
|
Spain |
0.5 |
0.6 |
28.2% |
|
Australia |
0.4 |
0.5 |
33.5% |
|
Japan |
0.9 |
1.2 |
42.1% |
|
India |
2.1 |
3.1 |
55.4% |
|
China |
3.5 |
5.0 |
48.2% |
Feasible Expansion Models Shaping the SIRS Treatment Market
The necessity to prioritize the mitigation of primary loopholes, such as lack of local supply chain, additional production costs, and manual inventory & patient management, is becoming the highlighted trend in this sector. The strategic public-private formations and operations are proving their crucial role as a driving fuel in the systemic inflammatory response syndrome treatment market. Additionally, the utilization of favorable government initiatives and policies is boosting the financial and commercial output in this field. For instance, in 2023, the implementation of a new ICU protocol in Germany escalated the nationwide adoption of SIRS combo therapy by 18.4%, as per the estimations from the Robert Koch Institute.
Key Feasibility Models
|
Model |
Region |
Financial Impact |
Key Driver |
|
Hospital Partnerships |
India |
12.5% Increment in Revenue Generation |
Generic Drug Procurement Reforms |
|
AI Integration in Diagnostics |
U.S. |
Additional USD 320.4 million Revenue Generation |
CDC-Mandated Sepsis Detection |
|
API Localization |
Europe |
15.3% Cost-reduction in Production |
Post-COVID Supply Chain Resilience |
Challenge
- Disparities in affordability and availability: Despite the gradual growth in developed landscapes, the systemic inflammatory response syndrome treatment market still lacks resources in underserved regions. The slow and limited penetration of advanced solutions in price-sensitive countries, such as China and India, often becomes a major hurdle for pioneers in globalizing their portfolios. Besides, the product’s expensiveness and the absence of adequate reimbursement policies also hinder wide adoption in these marketplaces. However, the introduction of generics is helping companies mitigate these issues. For instance, in 2024, Sun Pharma availed monthly biosimilars for USD 50.1, capturing 25.4% of the India market.
Systemic Inflammatory Response Syndrome Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7% |
|
Base Year Market Size (2024) |
USD 8.5 billion |
|
Forecast Year Market Size (2037) |
USD 18.8 billion |
|
Regional Scope |
|
Systemic Inflammatory Response Syndrome Treatment Segmentation
Treatment Type (Antibiotics, Immunomodulators, Corticosteroids, Vasopressors)
Based on treatment type, the immunomodulators segment is expected to hold the largest share of 32.4% in the systemic inflammatory response syndrome treatment market by 2037. Its high efficacy in reducing mortality makes this segment a priority for both drug developers and consumers. In this regard, the 2023 CDC report demonstrated a 40.2% mortality reduction in sepsis due to early intervention with this therapy. Moreover, the specificity in targeting affected or inflated cells has introduced a revolutionary asset for global leaders in this field. In this regard, the revenue generation by targeted immunomodulators is projected to reach up to USD 3.0 billion by 2030 in the U.S., Germany, and Japan landscapes. Furthermore, increasing R&D investments are fueling its dominance over other sub-types.
End user (Hospitals, Specialty Clinics, Research Institutes)
In terms of end user, the hospitals segment is predicted to dominate the systemic inflammatory response syndrome treatment market with a share of 58.2% over the assessed timeline. The presence of adequate infrastructure and supervision professionals makes these medical settings the most preferred point of care for patients. Additionally, the availability of better financial support and a standardized approach helps this segment create greater scopes for garnering lucrative revenues. For instance, bulk procurement in these organizations made ICU SIRS treatment 25.1% less expensive than clinics in 2024. Simultaneously, 80.0% of the public hospitals in India present an opportunity for biosimilar anti-TNFα therapies to exhibit an exceptional CAGR of 18.3%.
Our in-depth analysis of the global market includes the following segments:
Treatment Type |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSystemic Inflammatory Response Syndrome Treatment Industry - Regional Synopsis
North America Market Analysis
North America is poised to capture the highest share of 42.4% of the global systemic inflammatory response syndrome treatment market throughout the discussed timeframe. The region’s dominance is pledged to its well-established healthcare infrastructure and regulatory favors. These factors are cumulatively influencing both domestic and international pioneers to introduce innovative SIRS solutions for afflicted individuals. The enlarging population of sepsis patients in developed countries, such as the U.S. and Canada, is also fueling demand in this landscape. In this regard, the CDC revealed that the yearly occurrence and fatalities of this condition among adults in the U.S. were recorded to cross 2.0 million and 270,000 in 2023.
Considering the widespread associated ailments, several public authorities in the U.S. are heavily investing in developments in the market. For instance, in 2023, the yearly domestic investments in cytokine-targeting biologics accounted for USD 3.5 billion. In the same year, Federal funding for associated curatives surpassed USD 5.2 billion. Additionally, they are focusing on cultivating local sources and supply channels to make related therapeutics and other essentials more accessible for citizens, fueling adoption in this sector. Furthermore, the continuously magnifying reimbursement coverage is acting as a financial cushion for patients. In this regard, CMS mentioned that the U.S. Medicare spending in this category rose by 15.5% from 2020 to 2024.
APAC Market Statistics
The Asia Pacific systemic inflammatory response syndrome treatment market is anticipated to register the fastest pace of growth by the end of 2037. The region’s propagation is fueled by rapid infrastructural development and ongoing government initiatives in the healthcare industry. This is fostering a lucrative business environment for both domestic and global leaders in this field. Additionally, the increasing adoption of AI-based diagnostic and disease management tools is procuring consumers’ faith, stimulating regionwide acceptability of advanced solutions. For instance, in 2023, the integration of AI helped Japan reduce sepsis mortality by 25.3%. Moreover, the continuous expansion of the sepsis patient pool is also attracting pharma producers to participate in this merchandise.
The market in China is highly influenced by proactive government participation and contribution to domestic SIRS production. In this regard, the National Medical Products Administration observed a 15.4% rise in SIRS-related spending from 2018 to 2023 across this country. The frequent occurrence of this medical condition is pushing them to reform the nationwide healthcare infrastructure and medicine supply chain to accommodate the required solutions for every individual. China is also focusing on promoting the utilization and implementation of biosimilars as an affordable alternative to expensive conventional treatments, helping reduce the financial burden on patients. For instance, the strategic centralized procurement lowered drug prices by 30.1% in 2023.
Companies Dominating the Systemic Inflammatory Response Syndrome Treatment Landscape
The current scenario of the systemic inflammatory response syndrome treatment market represents a healthy competency among key players. They are increasingly investing in R&D cohorts to explore the extensive potential of their existing pipelines. Additionally, their heavy investments in drug discovery, coupled with strategic commercial and public-private alliances, are benefiting them with greater revenue generation while fostering new business opportunities in various disciplines. For instance, in 2023, Pfizer invested USD 2.2 billion in the commencement of a clinical trial on its IL-6 inhibitor. Simultaneously, in the same year, Roche formed a consortium of AI-powered diagnostics with more than 92 hospitals in Europe. Such events replicate the ongoing global expansion of this sector.
Below are the areas covered for each company under the top 20 global manufacturers:
|
Company Name (Country) |
Revenue Share (in %) |
Industry Focus |
|
Pfizer (USA) |
12.8 |
Leading developer of immunomodulators (e.g., IL-6 inhibitors) & antibiotics. |
|
Roche (Switzerland) |
10.9 |
AI-driven sepsis diagnostics & monoclonal antibodies. |
|
Novartis (Switzerland) |
9.5 |
TNF-α inhibitors & combination therapies for ICU use. |
|
GlaxoSmithKline (UK) |
8.7 |
Broad-spectrum antibiotics & vaccine adjuvants for SIRS prevention. |
|
Merck & Co. (USA) |
7.6 |
Vasopressors & novel anti-inflammatory biologics. |
|
Sanofi (France) |
xx |
Pediatric SIRS formulations & rapid diagnostic tools. |
|
Johnson & Johnson (USA) |
xx |
Sepsis management devices & corticosteroid therapies. |
|
AstraZeneca (UK) |
xx |
Precision immunomodulators & ICU-tailored drug delivery systems. |
|
Eli Lilly (USA) |
xx |
JAK inhibitors & sepsis-related cytokine storm therapies. |
|
Takeda Pharmaceutical (Japan) |
xx |
Plasma-derived therapies & Japan-focused SIRS protocols. |
|
Daiichi Sankyo (Japan) |
xx |
Low-cost generics & anticoagulants for SIRS complications. |
|
CSL Limited (Australia) |
xx |
Plasma protein therapies for severe inflammation. |
|
Sun Pharma (India) |
xx |
High-volume generics & India-centric affordable biosimilars. |
|
Lupin (India) |
3.3 |
Antibiotics & partnerships with public hospitals in emerging markets. |
|
Samsung Bioepis (South Korea) |
3.0 |
Biosimilars of anti-TNFα drugs & APAC market expansion. |
|
Celltrion (South Korea) |
2.9 |
Monoclonal antibodies & portable SIRS diagnostic kits. |
|
Hikma Pharmaceuticals (UK) |
2.6 |
Injectable antibiotics for MENA & European ICUs. |
|
Biocon (India) |
2.0 |
Biosimilar immunomodulators & cost-effective APIs. |
|
Pharmaniaga (Malaysia) |
1.5 |
Government-contracted generics & ASEAN distribution networks. |
|
Mesoblast (Australia) |
1.3 |
Stem cell therapies for refractory SIRS cases. |
In the News
- In March 2025, Roche gained acceptance for its supplemental Biologics License Application for Gazyva/Gazyvaro (obinutuzumab) from the FDA. This was based on the positive results from the phase III REGENCY study, demonstrating improved complete renal response in lupus nephritis.
- In March 2024, Pfizer announced the 2nd quarter financial results after the launch of its CytokineX-IL6 inhibitor, treating refractory SIRS in sepsis patients. It generated a revenue of USD 320.4 million, boosting the output from its immunomodulator portfolio by 12.3%.
Author Credits: Radhika Pawar
- Report ID: 3013
- Published Date: May 21, 2025
- Report Format: PDF, PPT
